Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25313711 | 0.89 | NFE2L2 (0.35) | NFE2L2ERN1POLBF2RL3 | |
| SCHEMBL30287307 | 0.83 | OXTR (0.38) | ERN1KDM4EUBE2NNPSR1 | |
| SCHEMBL25275117 | 0.83 | OXTR (0.38) | ERN1KDM4EUBE2NNPSR1 | |
| SCHEMBL31019973 | 0.80 | CHRNB4 (0.37) | NFE2L2ERN1KDM4EUBE2NPOLB | |
| SCHEMBL25193028 | 0.80 | CHRNB4 (0.37) | NFE2L2ERN1KDM4EUBE2NPOLB | |
| SCHEMBL18190943 | 0.78 | GLA (0.40) | ERN1KDM4EUBE2NNPSR1 | |
| SCHEMBL30963578 | 0.73 | MEN1 (0.40) | NFE2L2KDM4EUBE2NPOLB | |
| SCHEMBL19385625 | 0.73 | MEN1 (0.40) | NFE2L2KDM4EUBE2NPOLB | |
| SCHEMBL28996379 | 0.71 | ERN1 (0.41) | ERN1POLBNPSR1 | |
| SCHEMBL30287363 | 0.71 | ERN1 (0.41) | ERN1POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767311-B2 | Acid secretion inhibitor and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-09-26 | — | — | US | disclosed |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767311-B2 | Acid secretion inhibitor and use thereof | SLC10A2, SLC10A1, ASIC1 | NFE2L2 1757/4885ERN1 2819/4885KDM4E 3961/4885 |
| US-20230192650-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | SLC10A2, SLC10A1, ASIC1 | NFE2L2 1448/4885ERN1 2693/4885KDM4E 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.